

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Cincinnati, OH – September 21, 2024

Conference Location	The Graduate Cincinnati 151 Goodman Drive Cincinnati, OH	Phone: (513) 487-3800 https://www.graduatehotels.com/cincinnati
Parking at the Conference	A parking structure adjacent to the Graduate Cincinnati owned by the University. The self-park rate \$10 per day A limited number of guest rooms are available on Friday evening for \$169 plus taxes	
Driving Directions	The Graduate is in the heart of the University of Cincinnati campus adjacent to the College of Medicine and just three miles north of downtown. Located just north of Martin Luther King Drive about equidistant between Highways 71 and 75	
Seminar Agenda and Syllabus Information	Registration begins at 7:30am in the Beast Auditorium . Please check the signage for any room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.	

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	Registration and View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	Advances in the Screening and Treatment of HCV <ul style="list-style-type: none"> • Updates on diagnostic approaches • Caring for At-risk populations – homeless, PWID, the incarcerated • Novel FDA Approved Direct Acting Anti-virals • Clinical Cases and Discussion
9:10 am	Hepatitis B: Epidemiology, History, Testing and Treatment <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The efficacy of HBV Vaccination and Anti-viral therapies of HBV • HBV Re-activation and the Latest studies from EASL and AASLD
9:40 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Global and US perspective on the growth of Delta Hepatitis • Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards • Testing and surveillance approaches • Real world outcome studies on HDV and HEV
10:15 am	Break and View exhibits
10:30 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> • A review of Pre-course lecture on end-stage liver disease • Complications of cirrhosis • Liver transplant in the era of DAA’s

	<ul style="list-style-type: none"> • Clinical cases to illustrate HE, HRS and/or Thrombocytopenia
11:05 am	Hepatocellular Carcinoma(HCC) - Screening and Disease Progression <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery • New studies showing cost effectiveness of surveillance post SVR • PRIUS Study (MRI vs US) Abbreviated MRI • 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC
11:40 am	Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options <ul style="list-style-type: none"> • Promising 1st and 2nd line therapies for liver cancer • New data on the benefit of downstaging • C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC • Checkpoint inhibitors and VEGE inhibitors
12:20 pm	<i>Luncheon and Product Information Session</i>
12:55 pm	<i>Dessert and View Exhibits</i>
1:05 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Causes and Markers of PBC • Coping with the clinical features of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid • Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar
1:55 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Alcohol consumption and malnutrition • Warning signs and intervention in alcohol-associated hepatitis • Promising therapeutic agents for AAH
2:30 pm	<ul style="list-style-type: none"> • <i>Break & View Exhibits</i>
2:45 pm	Steatotic Liver Disease: The new healthcare epidemic <ul style="list-style-type: none"> • New naming conventions for fatty liver disease: MASLD and MASH– what and why? • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Metabolic Liver Disease • The ‘unhealthy’ rise in MASLD in the US population and What can be done Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:20 pm	MASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH – Semaglutide and Resmitemon • MASH Diagnosis and Treatment case
4:00 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:15 pm
Post-program activities	Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome 30 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 30 minutes. Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting – 30 minutes

Attendee Cancellation, Substitution, Refund

Attendance Policies

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)TM**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**NAGA CHALASANI, MD**

Dr. Chalasani currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine. He previously served as the Director of the Division of Gastroenterology and Hepatology at the same institution from 2007 to 2020. He completed his medical education in India and subsequently completed Internal Medicine Residency and Gastroenterology & Hepatology subspecialty training at Emory University in Atlanta.

Dr. Chalasani, a practicing hepatologist, is considered an authority in the fields of nonalcoholic fatty liver disease (NAFLD) and drug induced liver injury (DILI), two highly significant public health problems. His research has been continuously funded by the National Institutes of Health since 1999. He published over 300 original papers, 3 Practice Guidelines, 47 book chapters/review articles and more than 500 abstracts..

Your Seminar Faculty**MARWAN GHABRIL, MD, FAASLD, AGAF**

Dr. Ghabril currently serves as a Professor of Medicine at Indiana University School of Medicine, in the Division of Gastroenterology and Hepatology. He completed his medical education in Ireland and subsequently completed Internal Medicine Residency at Thomas Jefferson University Hospital in Philadelphia and Gastroenterology & Hepatology and Transplant Hepatology subspecialty training at the Mayo Clinic in Jacksonville.

Dr. Ghabril, a practicing hepatologist, is an expert in the fields of liver transplantation and drug induced liver injury (DILI). He has published over 140 original papers, 3 Practice Guidelines, 3 book chapters/review articles and more than 250 abstracts.



ASHINA SINGH, MD

Dr. Ashina Singh grew up in Maryland and graduated from the University of Maryland School of Medicine in 2010. She then made her way to the University of Cincinnati Academic Health Center where she completed her internal medicine residency and gastroenterology fellowship. She then returned to the University of Maryland for her transplant hepatology fellowship. Following completion of her training she has worked as a practicing transplant hepatologist and gastroenterologist with interests in clinical informatics and using technology to augment healthcare and health education, the promotion of health equity amongst learners and patients, and she has a special interest in liver diseases in pregnancy and women's liver health. Her care philosophy is: "To treat my patients as I would my own family, with care, thoughtfulness, advocacy and compassion." She currently lives in Zionsville, IN with her husband and two children.



MICHAEL SCHOECH, MD

Michael Schoech received his MD from the University of Cincinnati. He trained in Internal Medicine at the University of Virginia and completed both his Gastroenterology and Transplant Hepatology fellowships at the University of Cincinnati. Currently, he is an Associate Professor of Medicine and serves as the Program Director of the Transplant Hepatology Fellowship at the University of Cincinnati College of Medicine.

Dr. Schoech's research interests center around liver transplantation and primary sclerosing cholangitis. He has held several leadership positions in the field.